Compare STRT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRT | TRDA |
|---|---|---|
| Founded | 1908 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.4M | 275.3M |
| IPO Year | 1996 | 2021 |
| Metric | STRT | TRDA |
|---|---|---|
| Price | $65.23 | $4.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | ★ $84.00 | $19.00 |
| AVG Volume (30 Days) | 49.5K | ★ 384.9K |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.17 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $439,195,000.00 | $25,421,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.38 | $156.96 |
| P/E Ratio | $53.18 | ★ N/A |
| Revenue Growth | ★ 5.24 | N/A |
| 52 Week Low | $57.01 | $4.11 |
| 52 Week High | $93.00 | $16.45 |
| Indicator | STRT | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 45.79 |
| Support Level | $59.35 | $4.11 |
| Resistance Level | $84.30 | $7.89 |
| Average True Range (ATR) | 2.10 | 0.47 |
| MACD | 0.71 | 0.09 |
| Stochastic Oscillator | 66.40 | 58.62 |
Strattec Security Corp designs automotive access company that designs and delivers safe, secure, and engineered access solutions for the automotive and mobility markets. Built on generations of access and security engineering expertise, partner closely with OEMs to create differentiated, system level access experiences for end consumers. Its product portfolio spans the access journey from Permission, enabling secure vehicle entry through advanced mechanical and electronic systems; to Motion, delivering effortless, reliable powered access that enhances everyday usability; and through to Hold, providing precision engineered latching solutions.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.